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Abstract: Purpose: Little is known about the effectiveness of bright white light therapy (BWL) for
depressive symptoms in cancer survivors, many of whom prefer non-pharmacological treatments.
The purpose of this study was to compare the effectiveness of BWL versus dim red light therapy
(DRL) on depressive symptoms within individual cancer survivors using personalized (N-of-1) trials.
Methods: Cancer survivors with at least mild depressive symptoms were randomized to one of
two treatment sequences consisting of counterbalanced crossover comparisons of three-weeks of
lightbox-delivered BWL (intervention) or DRL (sham) for 30 min each morning across 12 weeks.
A smartphone application guided cancer survivors through the treatment sequence and facilitated data
collection. Cancer survivors tracked end-of-day depressive symptoms (primary outcome) and fatigue
using visual analog scales. Within-patient effects of BWL were assessed using an autoregressive
model with adjustment for linear time trends. Results: Eight of nine cancer survivors completed the
12-week protocol. Two survivors reported significantly (i.e., p < 0.05) lower depressive symptoms
(−1.3 ± 0.5 and −1.30 ± 0.9 points on a 10-point scale), five reported no difference in depressive
symptoms, and one reported higher depressive symptoms (+1.7 ± 0.6 points) with BWL versus DRL.
Eight of nine cancer survivors recommended personalized trials of BWL to others. Conclusions: There
were heterogeneous effects of three-week BWL on self-reported depressive symptoms among cancer
survivors, with some finding a benefit but others finding no benefit or even harm. Implications for
Cancer Survivors: Personalized trials can help cancer survivors learn if BWL is helpful for improving
their depressive symptoms.
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1. Introduction
More than one in five cancer survivors has elevated depressive symptoms, three-fold the prevalence
in the general population [1–3]. Depressive symptoms are a major contributor to poor quality of life in
cancer survivors [4]. Cancer survivors with depressive symptoms are also at risk of poor adherence to
preventive therapies, [5,6] worse prognosis, [7,8], and higher health care costs [9].
Even though evidence for their effectiveness is often lacking, complementary and alternative
medicine (CAM) treatments have become increasingly popular among cancer survivors, with up
to 80% of cancer survivors reporting CAM use at least once after diagnosis [10–12]. Among CAM
treatments for depressive symptoms, there is growing evidence in support of bright white light therapy
(BWL) [13]. Recent small randomized clinical trials (RCTs) suggest that BWL may be effective for
reducing depressive symptoms and fatigue in cancer survivors [14–16]. RCTs, however, estimate the
effect of BWL for the average patient in the trial, and provide limited information on the treatment
effect that an individual patient can expect to receive.
Personalized trials represent an innovative approach to determining the effectiveness of BWL
in cancer survivors [17]. Key features of personalized trials, also known as N-of-1 trials, include a
within-subject crossover design with treatment reversals, systematic collection of data on treatment
effects, and visualization of data such that patients can share in decision-making about the relative
benefits and harms of treatments [18,19]. When conducted successfully, such trials can provide the
highest level of evidence for clinical decision-making [20,21]. This design is particularly useful when
there is uncertainty regarding whether a treatment is likely to be effective for a given patient [22–24].
Thus, personalized trials can help fill the evidence gap regarding BWL by helping cancer survivors
learn, through their own guided experiment, whether BWL is helpful for them.
Accordingly, our goal was to conduct a series of personalized trials comparing BWL with dim red
light sham treatment (DRL) within individual depressed cancer survivors. The trials were enabled
by a smartphone application that was specifically developed for this use case. We hypothesized that
there would be heterogeneous effects of BWL on depressive symptoms, with some patients obtaining
significant benefits and others finding no benefits in comparison with DRL.
2. Materials and Methods
2.1. Customization of N-of-1Trial Smartphone Application and Electronic Platform
We partnered with Overlap Health, Inc. (West Hollywood, Florida) to create a smartphone
application for conducting personalized trials of light therapy. The application was designed to (1)
guide a patient through a multiple crossover design experiment comparing a bright white (10,000
lux) and a dim red lightbox (50 lux), (2) collect ambulatory assessments of depressive symptoms,
fatigue, and side-effects, (3) store and transmit data in a HIPAA-certified manner, (4) aggregate data by
treatment period, and (5) visualize data across intervention and sham periods in a manner that helps
patients determine whether BWL was effective for them.
2.2. Eligibility, Recruitment, and Consent
Implementation of this trial followed the CONSORT (Consolidated Standards of Reporting Trials)
2015 CENT (extension for reporting N-of-1 trials) Statement. (1) Patients were eligible if they were
21 years or older, English speaking, and used an iOS smartphone (i.e., iPhone), a requirement for
using the application. Patients also had to have at least mild depressive symptoms (eight-item patient
health questionnaire (PHQ-8) score 5–24). (2) Patients who reported suicidal ideations or a history of
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other severe mental illness (i.e., psychotic disorder or bipolar disorder) were ineligible. Patients were
also ineligible if chemotherapy, radiation, or surgery was planned for the subsequent 12 weeks, if life
expectancy was less than six months, or if unavailable for follow-up during the 12-week study period.
Patients were identified by promoting the study to clinicians affiliated with Columbia University
Irving Medical Center’s (CUIMC) cancer center. The study was also posted on the CUIMC website
“Recruit Me”, on Clinicaltrials.gov (NCT0316737), and on various websites and message boards of
organizations serving cancer survivors. Flyers included a URL that allowed patients to conduct
prescreening electronically. Those who remained eligible after prescreening were invited to meet with
the study coordinator to confirm eligibility, to have the full study protocol explained, and to provide
written signed informed consent. The Institutional Review Board of CUIMC approved the study
protocol (IRB-AAAR1273).
2.3. Personalized Trial Protocol
With the assistance of a research coordinator, patients downloaded the smartphone application
onto their iPhone from the App Store. Patients were then instructed to use one of two small (6” ×
5” × 1”), portable lightboxes (Litebook Advantage, Litebook®, Ltd. Medicine Hat, Toronto, Canada)
each morning for 30 min per day, three weeks at a time, for a total of 12 weeks, or six weeks with
each lightbox. They were told to keep the lightbox within their field of vision and within arm’s length
during use. One of the lightboxes, labeled A, emitted bright white light (~465 nm) equivalent to an
intensity of 10,000 lux when at a distance of 20”–24” (active treatment). The other lightbox, labeled B,
was identical appearing when turned off, but emitted dim red light (~633 nm) at an intensity of 50
lux, an insufficient light intensity to activate the melanopsin-producing cells from the retina (sham
treatment) [25]. The application then guided the patient through the personalized trial protocol by
sending push notification reminders to use the appropriate lightbox (A or B) each morning and to
complete end-of-day assessments of mood and fatigue. At the end of the 12-week period, the patient
met with the study coordinator to review the visualizations of their personalized trial data and discuss
treatment preferences.
2.4. Randomization and Blinding
Randomization to one of two balanced treatment sequences (i.e., bright white-dim red-dim
red-bright white or dim red-bright white-bright white-dim red) took place after eligibility was
confirmed. Balanced treatment sequences were used to decrease the potential for linear time effects
to bias the understanding of treatment effects [19]. A random number generator in the statistical
program R was used to assign patients to one of the treatment sequences. The research coordinator
then distributed the appropriately labeled lightboxes while being blinded to the treatment sequence.
Patients were informed that the goal of the study was to learn which lightbox was best for them
and were not told which lightbox was expected to be the active treatment. Study personnel responsible
for assessing outcomes were masked to the treatment sequence assignment until the completion of the
personalized trial. The statistician comparing within-patient effects of BWL and DRL was also masked
to treatment sequence assignment.
2.5. Outcomes
2.5.1. Depressive (Primary) and Fatigue Symptoms
At the end of each day (patients selected the time), patients received a push notification asking
them to report their depressive symptoms and fatigue using standard single-item visual analog scale
(VAS) items found to be reliable and valid affective symptom measures in prior studies: “How sad or
depressed were you today?” (0—not at all depressed to 10—extremely depressed), and “How tired or
fatigued were you today?” (0—not at all tired to 10—extremely tired) [26].
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2.5.2. Side Effects
During daily push notifications reminding patients to use the appropriate lightbox, patients were
also asked whether they had any side-effects from the lightbox, and if so, to describe them using a free
text entry.
2.5.3. Lightbox Preference
After completing the personalized trial, patients reviewed the results with the study coordinator,
and then stated their preferred treatment (i.e., BWL, DRL, or neither), likelihood of continuing to use
the preferred lightbox (1—“not at all likely” to 4—“very likely”), helpfulness of participation in the
personalized trial (1—“not at all helpful” to 4—“very helpful”), and how much they would recommend
personalized trials of light therapy to other depressed cancer survivors (1—“not at all” to 5—“very
much”).
2.5.4. Other Measures
At enrollment, patients’ sociodemographic characteristics (age, gender, race, ethnicity,
years of education, employment status, health insurance status), cancer history (type of cancer,
treatment modalities), depression history (prior diagnosis of depression, use of antidepressants,
psychotherapy, or CAM for depression), other medical history (number of medications and comorbid
conditions), and preference for shared decision-making [27] were obtained through self-report. At the
final interview, patients were asked to describe the ease of using the smartphone application.
2.6. Data Visualization
Over the course of the personalized trial, patients could view their average symptom scores per
treatment period (Figure A1, Panel a). At the end of the trial, they were provided with a column graph
that visualized their average symptoms during the personalized trial, grouped by treatment period
(Figure A1, Panel b). Statistically significant differences in symptoms were highlighted by including a
checkmark corresponding to the lightbox that resulted in lower symptoms.
2.7. Sample Size Estimate
In personalized trials, sample size refers to the number of assessments and treatment periods for
each patient. As we had no prior data from which to estimate within-patient day-to-day variability in
depressive symptoms nor an expected effect size for depressive symptom reduction when comparing
BWL to DRL, we did not calculate statistical power a priori for the number of treatment periods or
number of assessments per treatment period. Rather, the sample size for each personalized trial was
based on collecting the maximal amount of data expected to be tolerable from the perspective of patient
study burden. In prior focus groups assessing patient preferences for the design of personalized trials,
a 12-week study duration with 5 min of assessments per day was viewed as the upper limit of what
patients would comply with, and this corresponded to the duration and intensity of self-assessments
used in this study [17].
2.8. Statistical Analyses
Descriptive statistics were used to describe patients in the study. To determine whether BWL
was superior to DRL for reducing depressive symptoms for individual patients, treatment effects
were assessed using an autoregressive model that included the type of light therapy as the main
exposure, adjusted for time (e.g., days since enrollment) linearly as a covariate, and accounted for
autocorrelations of the order 1. Statistical significance was defined as p < 0.05. Given substantial
heterogeneity in the within-patient effects of BWL, data were not pooled across patients.
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2.9. Data Availability
Data available on request from the authors.
3. Results
Between 1 September 2017 and 1 May 2018, 47 cancer survivors completed the prescreening
questionnaire, and 15 were eligible for the personalized trial of light therapy. Nine cancer survivors
were assigned to this series of personalized trials comparing BWL versus DRL (Figure 1). Six patients
were assigned to personalized trials comparing two sham treatments (dim white versus dim red light),
which are not further discussed here. The mean age of these nine patients was 54 years, 78% were
women, 78% were white, and 33% were Hispanic (Table 1). The most common type of cancer was breast
cancer (56%). None had metastatic disease. Two-thirds of patients had at least moderate depressive
symptoms (i.e., PHQ-8 score ≥ 10) and the mean PHQ-8 score was 10. Most patients (seven out of
nine) were already engaging in some form of depression treatment, and most patients (six out of nine)
preferred shared decision-making with their doctor.
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Table 1. Baseline patient characteristics (N = 9). 
Characteristic Mean (SD) or n (Percentage) 
Age in years, mean (SD) 54.2 (17.7) 
Female 7 (78%) 
Hispanic 3 (33%) 
Race:  
White 7 (78%) 
Black 1 (11%) 
Other 1 (11%) 
Cancer type:  
Breast 5 (56%) 
Thyroid 2 (22%) 
Bone 1 (11%) 
Skin 1 (11%) 
Prior cancer treatment:  
Surgery 7 (78%) 
. fl . r i ti : / ,
ite light therapy (W, RW/WR, bal nced treatment sequence b ginn g with dim red light (R).
Overall, eight out of nine patients completed the 12-week personalized trial, the ninth patient
dropped out of the trial in the third week due to p rceived lack of benefits of either type of l ght therapy.
For the eight patients who completed the protocol, dep essive sympt m assessments w e recorded on
72.0% of p ssible days (i.e., 60.5 SD 8.8 days out of a p ssib e 84 day total)
3.1. Outcomes and Estimation
The results of the individual personalized trials are presented in Table 2 and in Figure A2. Overall,
BWL was associated with significantly fewer patient-reported depressive symptoms in two patients,
no significant difference in five patients, and worse depressive symptoms in one patient (Figure 2). A
similar pattern was observed with respect to fatigue symptoms, with just one patient reporting lower
fatigue, six patients reporting no difference in fatigue severity, and one patient reporting higher fatigue
with BWL versus DRL.
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Table 1. Baseline patient characteristics (N = 9).
Characteristic Mean (SD) or n (Percentage)

















Depressed (PHQ8 ≥ 10) 6 (67%)
PHQ-8 score, mean (SD) 9.7 (2.2)
Current depression treatment:
Receiving any depression treatment 7 (78%)
Prescribed antidepressants 4 (44%)
Receiving psychotherapy 6 (67%)
Complementary and alternative medicine 3 (33%)
Decision-making preference:
I want doctor to decide 0 (0%)
I want doctor to consider my ideas 1 (11%)
I want doctor and I to make decisions together 6 (67%)
I want to decide 2 (22%)
PHQ-8—patient health questionnaire; SD—standard deviation.
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Table 2. Characteristics and outcomes of personalized trials of light therapy for depressive symptoms (N = 9).
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Table 2. Cont.
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Abbreviations: W, bright white light therapy; R, dim red light therapy; SE, standard error. Depressive and fatigue symptoms were assessed at the end of each day on a scale from 0 (none)
to 10 (severe). † Assessments were interrupted in the middle third of the study due to an interruption in the smartphone application.
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3.2. Harms
Only one patient reported any adverse effects from either lightbox. This patient reported
mild headaches during eight days of the first three-week treatment period with BWL. However,
these headaches were not severe enough for the patient to discontinue the personalized trial, and this
side-effect was not reported during the second BWL treatment period.
3.3. Light Therapy Preferences and Overall Satisfaction with Personalized Trial
Overall, four patients preferred BWL, one preferred DRL, and four had no preference. Five patients
reported being likely to continue using their preferred lightbox after the personalized trial was over.
The patient who preferred DRL reported that he found the light soothing and helpful with his morning
meditation. Preferences for light therapy were consistent with the data presented to patients in
seven out of nine patients, two patients preferred BWL despite reporting no significant differences
in depressive symptoms between lightboxes. With respect to overall satisfaction, six patients would
“very much” recommend and two would “a little bit” recommend participation in a personalized
trial of light therapy to other cancer survivors with depressive symptoms, only one patient would
not recommend participation. All patients reported that the application was easy to use, and none
were bothered by the effort needed to self-track mood and fatigue. Those few concerns that were
raised regarding personalized trial participation pertained to the time burden and inconvenience of
completing 30 min of light therapy each morning.
4. Discussion
This study addressed whether smartphone application-delivered personalized trials could be
a helpful tool for personalizing the selection of BWL for depressive symptoms in cancer survivors.
Substantial heterogeneity in the effect of BWL on depressive symptoms was uncovered, with a subset of
patients finding benefits, a subset finding no benefit, and, in one patient, possibly harm. While a small
sample, two out of nine patients identified a clinically significant reduction in self-reported depressive
symptoms over a sham, which is comparable to the number needed to treat with antidepressants
for one patient to obtain benefits over placebo in primary care [28]. Of note, the effectiveness of
antidepressant medications in cancer survivors remains uncertain [29].
One surprising finding was that one patient reported higher depressive symptoms with BWL
compared to DRL, and this patient preferred DRL over BWL. To our knowledge, prior studies
have not reported depressogenic effects of BWL. Future studies should seek to determine if this
finding is replicable, and if so, through which biological mechanisms. One possibility is that rather
than BWL causing harm, DRL could have had a beneficial effect. DRL at the intensity provided
in the study was expected to be physiologically inert with respect to the melanopsin pathway [30].
Nevertheless, there could have been other pathways through which DRL exerted its effects. The one
patient who preferred DRL believed that it induced a calming effect. This anecdote highlights the
unique potential for personalized trials to provide patients with singular insights that could never
be appreciated in a conventional RCT in which participants are only exposed to one treatment.
Future studies of light therapy should seek to better understand the heterogeneous effects of BWL and
DRL. Pairing personalized trials with biological data (e.g., melatonin levels or 24-hour rest-activity
behavioral rhythms) to more deeply phenotype patients may help better understand the effects of
light therapy and could result in biomarkers that personalize the selection of light therapy without
necessitating an N-of-1 experimental design.
Few prior studies have employed a personalized trials approach to individualize the selection
of treatments for depression, and to our knowledge, none have evaluated the effectiveness of light
therapy in this manner [31]. One of the requirements of the multiple crossover design component of
personalized trials is that treatments are reversible and have a sufficiently short onset and washout
period to enable crossovers to occur in a feasible time period. Psychotherapy is often considered
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insight-oriented, and so is not easily reversible. While conventional antidepressant medications are
theoretically reversible, and so technically amenable to a personalized trial approach, withdrawal
effects and the timeline for onset and offset suggest that other treatments, such as light therapy, may be
more suitable for testing with multiple crossover designs.
4.1. Limitations
There were several limitations to our study. First, we assessed depressive symptoms using a
single end-of-day VAS question, and this is not analogous to understanding treatment effects using
a psychiatric interview or other more detailed depressive symptom assessments. Nevertheless,
single item mood scales are more feasible for daily administration and have been strongly associated
with longer instruments and clinical interviews in prior studies [26,32]. Our protocol included only
one treatment repetition and our analysis plan accounted for only two possible confounders (i.e.,
linear trend, autocorrelation), and thus may have misattributed differences in depressive symptoms to
BWL. The treatment period was limited to three weeks. While prior studies have shown that BWL
can reduce depressive symptoms in as few as two weeks, a longer duration of BWL may have been
needed to impact depressive symptoms in some patients [33]. The impact of seasonality was not
considered. Adherence to light therapy was not objectively assessed. Future personalized trials of this
nature may wish to better establish baseline symptoms prior to initiating light therapy to help clarify
treatment effects. A small number of patients were enrolled. Thus, assessments of the feasibility of the
smartphone-delivered personalized trial and of the pooled effect of BWL on depressive symptoms
should be interpreted cautiously.
4.2. Generalizability
We enrolled a small number of English-speaking cancer survivors who use smartphones into
our study, which limits the understanding of the generalizability of the findings to other cancer
survivors. Nevertheless, smartphones are increasingly ubiquitous, and an application could easily be
translated into Spanish [34]. We also excluded cancer survivors undergoing primary cancer treatments,
as personalized trials are challenging to interpret when multiple possible confounders of treatment
effects occur across time.
5. Conclusions
The personalized trials approach used in this study brought back the focus on the individual
person that existed before the convention of pooling across many persons in between-subject RCTs [35].
We determined that there were heterogeneous treatment effects for BWL, with some patients finding a
benefit and others no benefit or even harm. Further, the majority of patients recommended personalized
trials of light therapy to others. Personalized trials may be ideally suited to testing the effectiveness of
relatively short-acting depression treatments in cancer survivors, particularly emerging treatments for
which we have a limited understanding of treatment effects.
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References 
1. Mitchell, A.J.; Chan, M.; Bhatti, H.; Halton, M.; Grassi, L.; Johansen, C.; Meader, N. Prevalence of 
depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: 
A meta-analysis of 94 interview-based studies. Lancet Oncol. 2011, 12, 160–174. 
2. Linden, W.; Vodermaier, A.; Mackenzie, R.; Greig, D. Anxiety and depression after cancer diagnosis: 
Prevalence rates by cancer type, gender, and age. J. Affect. Disord. 2012, 141, 343–351. 
3. Pirl, W.F. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. 
JNCI Monogr. 2004, 32, 32–39. 
4. Arrieta, Ó.; Angulo, L.P.; Núñez-Valencia, C.; Dorantes-Gallareta, Y.; Macedo, E.O.; Martínez-López, D.; 
Alvarado, S.; Corona-Cruz, J.F.; Oñate-Ocaña, L.F. Association of depression and anxiety on quality of life, 
treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann. Surg. Oncol. 
2013, 20, 1941–1948. 
5. Mausbach, B.T.; Schwab, R.B.; Irwin, S.A. Depression as a predictor of adherence to adjuvant endocrine 
therapy (AET) in women with breast cancer: A systematic review and meta-analysis. Breast Cancer Res. 
Treat. 2015, 152, 239–246. 
6. DiMatteo, M.R.; Lepper, H.S.; Croghan, T.W. Depression is a risk factor for noncompliance with medical 
treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 
2000, 160, 2101–2107. 
7. Pinquart, M.; Duberstein, P.R. Depression and cancer mortality: A meta-analysis. Psychol. Med. 2010, 40, 
1797–1810. 
8. Satin, J.R.; Linden, W.; Phillips, M.J. Depression as a predictor of disease progression and mortality in 
cancer patients: A meta-analysis. Cancer 2009, 115, 5349–5361. 
9. Pan, X.; Sambamoorthi, U. Health care expenditures associated with depression in adults with cancer. J. 
Community Support Oncol. 2015, 13, 240–247. 
10. Richardson, M.A.; Sanders, T.; Palmer, J.L.; Greisinger, A.; Singletary, S.E. Complementary/alternative 
medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18, 
2505–2514. 
11. Owen, D.K.; Lewith, G.; Stephens, C.R. Can doctors respond to patients’ increasing interest in 
complementary and alternative medicine? BMJ 2001, 322, 154–158. 
12. Mao, J.J.; Palmer, C.S.; Healy, K.E.; Desai, K.; Amsterdam, J. Complementary and alternative medicine use 
among cancer survivors: A population-based study. J. Cancer Surviv. 2011, 5, 8–17. 
Figure 2. Individual patient-level plots f depressive symptoms over the course of each pers nalized
trial for eight patients who completed t e 12-week protocol. Black dots refer to bright whit light therapy
treatment periods, and red dots refer to dim red light therapy treatment periods. Sy ptoms were
repor ed at the nd of the day using a 0 (no depressive symptoms) to 10 (s vere depre sive symptoms)
visual analog scale.
eferences
1. itche l, .J.; Chan, M.; Bhatti, H.; alton, M.; Grassi, L.; Johansen, C.; Meader, N. Prevalence of depressi n,
anxi ty, a d adjustme t disorder in oncological, haemat logical, and palliative-c re settings: A meta-analysis
of 94 interview-based studies. Lanc t Oncol. 2011, 12, 160–174. [CrossRef]
2. Linden, .; V er aier, .; ackenzie, R.; Greig, D. nxiety and depre sion after cancer diagnosis:
Prevalence rates by ca cer t , , . J. ff t. is r . 2012, 141, 343–351. [CrossRef] [PubMed]
3. Pirl, .F. i ce r rt t e cc rre ce, assess ent, and treat ent of depre sion in cancer patients.
JNCI onogr. 2004, 32, 32–39. [CrossRef] [PubMed]
4. Arrieta, Ó.; Angulo, L.P.; úñez-Valencia, .; orantes-Gallareta, Y.; acedo, E. .; artínez-López, D.;
lvarado, S.; Corona-Cruz, J.F.; ñate- caña, L.F. ssociation of depression and anxiety on quality of life,
treat ent adhere ce, a r sis i atie ts it a a ce -s all cell l ca cer. nn. Surg. Oncol.
2013, 20, 1941–1948. [CrossRef] [PubMed]
5. ausbach, B.T.; Sch ab, R.B.; Ir in, S.A. epression as a re ictor of a erence to a j vant e ocrine
therapy ( ) in o en with breast cancer: A systematic review and meta-analysis. Breast Cancer Res. Treat.
2015, 152, 239–246. [CrossRef] [PubMed]
6. Di atteo, .R.; Lepper, .S.; Croghan, T. . epression is a risk factor for nonco pliance ith edical
treat ent: Meta-analysis of the effects of anxiety and depression on patient adherence. rch. Intern. Med.
2000, 160, 2101–2107. [CrossRef]
7. Pinquart, .; uberstein, P.R. epression and cancer ortality: eta-analysis. Psychol. Med. 2010, 40,
1797–1810. [CrossRef]
8. Satin, J.R.; Linden, .; Phillips, M.J. Depression as a predictor of disease progression and mortality in cancer
patients: A meta-analysis. Cancer 2009, 115, 5349–5361. [CrossRef]
9. Pan, X.; Sambamoorthi, U. Health care expenditures associated with depression in adults with cancer.
J. Community Support Oncol. 2015, 13, 240–247. [CrossRef]
10. Richardson, .A.; Sanders, T.; Pal er, J.L.; Greisinger, A.; Singletary, S.E. Co ple entary/alternative
medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18,
2505–2514. [CrossRef]
11. Owen, D.K.; Lewith, G.; Stephens, C.R. Can doctors respond to patients’ increasing interest in complementary
and alternative medicine? BMJ 2001, 322, 154–158. [CrossRef]
Healthcare 2020, 8, 10 13 of 14
12. Mao, J.J.; Palmer, C.S.; Healy, K.E.; Desai, K.; Amsterdam, J. Complementary and alternative medicine use
among cancer survivors: A population-based study. J. Cancer Surviv. 2011, 5, 8–17. [CrossRef]
13. Golden, R.N.; Gaynes, B.N.; Ekstrom, R.D.; Hamer, R.M.; Jacobsen, F.M.; Suppes, T.; Wisner, K.L.;
Nemeroff, C.B. The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis
of the evidence. Am. J. Psychiatry 2005, 162, 656–662. [CrossRef]
14. Johnson, J.A.; Garland, S.N.; Carlson, L.E.; Savard, J.; Simpson, J.S.A.; Ancoli-Israel, S.; Campbell, T.S.
Bright light therapy improves cancer-related fatigue in cancer survivors: A randomized controlled trial.
J. Cancer Surviv. 2018, 12, 206–215. [CrossRef]
15. Valdimarsdottir, H.B.; Figueiro, M.G.; Holden, W.; Lutgendorf, S.; Wu, L.M.; Ancoli-Israel, S.; Chen, J.;
Hoffman-Peterson, A.; Granski, J.; Prescott, N.; et al. Programmed environmental illumination during
autologous stem cell transplantation hospitalization for the treatment of multiple myeloma reduces severity
of depression: A preliminary randomized controlled trial. Cancer Med. 2018, 7, 4345–4353. [CrossRef]
16. Redd, W.H.; Valdimarsdottir, H.; Wu, L.; Winkel, G.; Byrne, E.E.; Beltre, M.A.; Liebman, E.S.; Erazo, T.;
Hayes, J.A.; Isola, L.; et al. Systematic light exposure in the treatment of cancer-related fatigue: A preliminary
study. Psychooncology 2014, 23, 1431–1434. [CrossRef]
17. Kronish, I.M.; Alcántara, C.; Duer-Hefele, J.; Onge, T.S.; Davidson, K.W.; Carter, E.J.; Medina, V.; Cohn, E.;
Moise, N. Patients and primary care providers identify opportunities for personalized (N-of-1) trials in the
mobile health era. J. Clin. Epidemiol. 2017, 89, 236–237. [CrossRef] [PubMed]
18. Duan, N.; Kravitz, R.L.; Schmid, C.H. Single-patient (n-of-1) trials: A pragmatic clinical decision methodology
for patient-centered comparative effectiveness research. J. Clin. Epidemiol. 2013, 66, S21–S28. [CrossRef]
[PubMed]
19. Duan, N.; Eslick, I.; Gabler, N.B.; Kaplan, H.C.; Kravitz, R.L.; Larson, E.B.; Pace, W.D.; Schmid, C.H.; Sim, I.;
Vohra, S. Design and Implementation of N-of-1 Trials: A User’s Guide; Kravitz, R., Duan, N., Eds.; Agency for
Healthcare Research and Quality: Rockville, MD, USA, 2014.
20. Guyatt, G.H.; Haynes, R.B.; Jaeschke, R.Z.; Cook, D.J.; Green, L.; Naylor, C.D.; Wilson, M.C.; Richardson, W.S.;
Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature: XXV. Evidence-based
medicine: Principles for applying the Users’ Guides to patient care. JAMA 2000, 284, 1290–1296. [CrossRef]
[PubMed]
21. Lillie, E.O.; Patay, B.; Diamant, J.; Issell, B.; Topol, E.J.; Schork, N.J. The n-of-1 clinical trial: The ultimate
strategy for individualizing medicine? Pers. Med. 2011, 8, 161–173. [CrossRef]
22. Johnston, B.C.; Mills, E. N-of-1 randomized controlled trials: An opportunity for complementary and
alternative medicine evaluation. J. Altern. Complement. Med. 2004, 10, 979–984. [CrossRef]
23. Vohra, S.; Shamseer, L.; Sampson, M.; Bukutu, C.; Schmid, C.H.; Tate, R.; Nikles, J.; Zucker, D.R.; Kravitz, R.;
Guyatt, G.; et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. J. Clin. Epidemiol.
2016, 76, 9–17. [CrossRef]
24. Kroenke, K.; Strine, T.W.; Spitzer, R.L.; Williams, J.B.; Berry, J.T.; Mokdad, A.H. The PHQ-8 as a measure of
current depression in the general population. J. Affect. Disord. 2009, 114, 163–173. [CrossRef]
25. Rea, M.S.; Figueiro, M.G.; Bierman, A.; Bullough, J.D. Circadian light. J. Circadian Rhythms 2010, 8, 2.
[CrossRef]
26. Ahearn, E.P. The use of visual analog scales in mood disorders: A critical review. J. Psychiatr. Res. 1997, 31,
569–579. [CrossRef]
27. Degner, L.F.; Sloan, J.A.; Venkatesh, P. The Control Preferences Scale. Can. J. Nurs. Res. 1997, 29, 21–43.
28. Arroll, B.; Elley, C.R.; Fishman, T.; Goodyear-Smith, F.A.; Kenealy, T.; Blashki, G.; Kerse, N.; MacGillivray, S.
Antidepressants versus placebo for depression in primary care. Cochrane Database Syst. Rev. 2009. [CrossRef]
29. Ostuzzi, G.; Matcham, F.; Dauchy, S.; Barbui, C.; Hotopf, M. Antidepressants for the treatment of depression
in people with cancer. Cochrane Database Syst. Rev. 2018. [CrossRef]
30. Lucas, R.J.; Peirson, S.N.; Berson, D.M.; Brown, T.M.; Cooper, H.M.; Czeisler, C.A.; Figueiro, M.G.; Gamlin, P.D.;
Lockley, S.W.; O’Hagan, J.B.; et al. Measuring and using light in the melanopsin age. Trends Neurosci. 2014,
37, 1–9. [CrossRef]
31. Kronish, I.M.; Hampsey, M.; Falzon, L.; Konrad, B.; Davidson, K.W. Personalized (N-of-1) Trials for depression:
A systematic review. J. Clin. Psychopharmacol. 2018, 38, 218–225. [CrossRef]
Healthcare 2020, 8, 10 14 of 14
32. Van Rijsbergen, G.D.; Burger, H.; Hollon, S.D.; Elgersma, H.J.; Kok, G.D.; Dekker, J.; de Jong, P.J.; Bockting, C.L.
How do you feel? Detection of recurrent Major Depressive Disorder using a single-item screening tool.
Psychiatry Res. 2014, 220, 287–293. [CrossRef] [PubMed]
33. Maruani, J.; Geoffroy, P.A. Bright light as a personalized precision treatment of mood disorders.
Front. Psychiatry 2019, 10, 85. [CrossRef] [PubMed]
34. Brown, A.; López, G.; Lopez, M.H. Digital Divide Narrows for Latinos as More Spanish-Speakers and Immigrants
Go On-Line; Pew Research Center: Washington, WA, USA, 2016.
35. Molenaar, P. A manifesto on psychology as idiographic science: Bringing the person back into scientific
psychology, this time forever. Measurement 2004, 2, 201–218. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
